Author

S. Leenstra

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Assay:proteomics· 1

Frequent Co-Authors

F. Fabro· 2 shared I. Ntafoulis· 2 shared M. L. M. Lamfers· 2 shared R. Tching Chi Yen· 2 shared A. Biswas· 1 shared A. C. O'Farrell· 1 shared A. Idbaih· 1 shared A. Kremer· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Fabro

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of inter- and intra-tumoral molecular phenotypes steering temozolomide resistance in patient-derived glioblastoma cells.

F. Fabro, T. V. Kers, K. J. Feller, C. Beerens, I. Ntafoulis, A. Idbaih, M. Verrault, K. Connor, A. Biswas, M. Salvucci, J. H. M. Prehn, A. T. Byrne, A. C. O'Farrell, D. Lambrechts, G. Dilcan, , S. Leenstra

This study identifies two molecular phenotypes, ADA and N-ADA, associated with temozolomide resistance in glioblastoma cells through bulk and single-cell RNA sequencing.

bioRxiv · Aug 11, 2023Cancer Biology

Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in GBM

F. Fabro, N. M. Kannegieter, E. L. de Graaf, K. Queiroz, M. L. M. Lamfers, A. Ressa, S. Leenstra

This study uses a novel kinase profiling platform to show drug efficacy and resistance in glioblastoma vary by patient and 2D/3D model.

bioRxiv · Jul 22, 2022Cancer Biology

Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell cultures

C. Verheul, I. Ntafoulis, T. Kers, Y. Hoogstrate, P. Mastroberardino, S. Barnhoorn, C. Payan, R. Tching Chi Yen, E. Struys, S. Koolen, C. Dirven, S. Leenstra, P. French, M. Lamfers

The paper establishes twelve patient-derived IDH1 mutant glioma cell cultures, confirms their similarity to parental tumors, and identifies nine FDA-approved drugs with activity against IDH-mutant gliomas.

bioRxiv · Apr 9, 2021 · PreprintCancer Biology